Stock Market Reviews

MIRM (Mirum Pharmaceuticals, Inc.) News

Get the latest news, insights, and market updates on MIRM (Mirum Pharmaceuticals, Inc.). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Should You Invest in Mirum Pharmaceuticals (MIRM)?
  TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 2.26% (gross) and 2.01% (net), compared to the Russell 2000 Growth Index’s 12.19% return. During the quarter, all asset classes except […]
  Jan 6, 2026 - $MIRM
• Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now
  These predictions were easy.
  Dec 30, 2025 - $MIRM
• Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line
  Selling shares usually signals doubt, but in this case the math points to something very different happening beneath the surface.
  Dec 28, 2025 - $MIRM
• What Analysts Think Is Changing the Story for Mirum Pharmaceuticals Now
  Mirum Pharmaceuticals stock is entering a new chapter as analysts lift their fair value estimate from $95.20 to $103.10, even while dialing back revenue growth expectations from 21.67% to 21.02%. A slightly lower discount rate of 7.15% versus 7.20% signals that markets see marginally less risk in the story, anchored by steady Livmarli performance and rising anticipation for volixibat data. Stay tuned to see how you can track these evolving assumptions and the shifting narrative around Mirum...
  Dec 25, 2025 - $MIRM
• This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone
  This biotech stock reached an all-time high and is in a buy zone. The company makes drugs for rare diseases.
  Dec 23, 2025 - $MIRM
• Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
  FOSTER CITY, Calif., December 19, 2025--Mirum Pharmaceuticals Announces Additional Private Placement Financing With TCGX
  Dec 19, 2025 - $MIRM
• Morgan Stanley Raises Mirum (MIRM) PT to $95 on Strategic Bluejay Acquisition, Brelovitug Pipeline Addition
  Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the high short interest stocks to buy right now. On December 9, Morgan Stanley analyst Michael Ulz raised the firm’s price target on Mirum Pharmaceuticals to $95 from $81 with an Overweight rating on the shares. Ulz informed investors that the acquisition of Bluejay is significant because it […]
  Dec 11, 2025 - $MIRM
• Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  FOSTER CITY, Calif., December 11, 2025--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Dec 11, 2025 - $MIRM
• Mirum Pharmaceuticals (MIRM): Assessing Valuation After Strong Long-Term Returns and Recent Share Price Pullback
  Mirum Pharmaceuticals (MIRM) has quietly turned into one of those rare-disease stories that rewards patient holders, with the stock up sharply over the past year despite recent pullbacks. See our latest analysis for Mirum Pharmaceuticals. With the latest share price at $64.67, the stock has cooled off in recent weeks, but that pullback sits against a powerful backdrop of strong year to date share price returns and exceptional multi year total shareholder returns, suggesting momentum is...
  Dec 11, 2025 - $MIRM
• Baird Lifts Mirum Pharmaceuticals, Inc. (MIRM) Price Target on Bluejay Therapeutics Acquisition
  Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Baird reiterated its Outperform rating on Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and raised the price target to $88 from $80. The price target hike follows the company’s agreement to acquire Bluejay Therapeutics for $620 million […]
  Dec 11, 2025 - $MIRM